Literature DB >> 20003096

Predicting the advent of ascites and other complications in primary biliary cirrhosis: a staged model approach.

C-W Chan1, E A Tsochatzis, J R Carpenter, C Rigamonti, F Gunsar, A K Burroughs.   

Abstract

BACKGROUND: Current survival models for primary biliary cirrhosis have limited precision for medium and long-term survival. Aim To describe a prognostic model for the advent of complications in primary biliary cirrhosis as the first approach to a staged prognostic model.
METHODS: From an established database of 289 consecutive primary biliary cirrhosis patients referred to Royal Free Hospital over 12 years (mean follow-up of 4.1 years), baseline characteristics at referral were evaluated by Cox-proportional hazards regression modelling.
RESULTS: The following complications occurred de novo: 85 ascites/peripheral oedema, 40 oesophagogastric varices, 63 encephalopathy, 29 spontaneous bacterial peritonitis and/or septicaemia, 59 symptomatic urinary tract infections. Age, albumin, log(10)(bilirubin), presence of ascites at referral, variceal bleeding within 6 weeks before referral, detection of oesophagogastric varices at or before referral were significant at multivariate analysis with different combinations and coefficients for each complication. The model for predicting ascites and/or peripheral oedema best fitted the observed data (ROC = 0.7682, S.E. = 0.0385).
CONCLUSIONS: The known prognostic factors in primary biliary cirrhosis also model the advent of complications. In view of the prognostic importance of ascites and its more robust statistical model, ascites and/or peripheral oedema could represent, following validation, the most suitable staged model in primary biliary cirrhosis to improve precision in survival modelling.

Entities:  

Mesh:

Year:  2009        PMID: 20003096     DOI: 10.1111/j.1365-2036.2009.04215.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  4 in total

1.  Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.

Authors:  Maren H Harms; Willem J Lammers; Douglas Thorburn; Christophe Corpechot; Pietro Invernizzi; Harry L A Janssen; Pier M Battezzati; Frederik Nevens; Keith D Lindor; Annarosa Floreani; Cyriel Y Ponsioen; Marlyn J Mayo; George N Dalekos; Tony Bruns; Albert Parés; Andrew L Mason; Xavier Verhelst; Kris V Kowdley; Jorn C Goet; Gideon M Hirschfield; Bettina E Hansen; Henk R van Buuren
Journal:  Am J Gastroenterol       Date:  2017-12-12       Impact factor: 10.864

2.  Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study.

Authors:  V Papastergiou; E A Tsochatzis; M Rodriguez-Peralvarez; M Rodriquez-Peralvarez; E Thalassinos; G Pieri; P Manousou; G Germani; C Rigamonti; V Arvaniti; S Karatapanis; A K Burroughs
Journal:  Aliment Pharmacol Ther       Date:  2013-10-05       Impact factor: 8.171

3.  Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis.

Authors:  Lukas Burghart; Emina Halilbasic; Philipp Schwabl; Benedikt Simbrunner; Albert Friedrich Stättermayer; Oleksandr Petrenko; Bernhard Scheiner; David Bauer; Matthias Pinter; Kaan Boztug; Mattias Mandorfer; Michael Trauner; Thomas Reiberger
Journal:  J Gastroenterol       Date:  2021-12-11       Impact factor: 7.527

4.  Ursodeoxycholic acid improves bilirubin but not albumin in primary biliary cirrhosis: further evidence for nonefficacy.

Authors:  Emmanuel A Tsochatzis; Maurille Feudjo; Cristina Rigamonti; Jiannis Vlachogiannakos; James R Carpenter; Andrew K Burroughs
Journal:  Biomed Res Int       Date:  2013-07-24       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.